Cowen launched coverage of Apollo Endosurgery (NASDAQ:APEN) with an “outperform” rating and $13 price target. The stock closed at $7.64 on Dec. 14. APEN is focused on design, development and commercialization of novel...
Cowen raised its price target for TransMedics (NASDAQ:TMDX) to $44 from $20, citing multiple catalysts ahead for all three of the company’s organ programs. The stock closed at $23.82 on Feb. 23. TransMedics has...
Cowen initiated coverage of Aziyo Biologics (NASDAQ:AZYO) with an “outperform” rating an $20 price target. The stock closed at $10.98 on Oct. 30. Aziyo is a regenerative medicine company that has a three-pronged...
Cowen launched coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating and $20 price target. The stock closed at $10.65 on Sept. 9. DermTech provides the only commercial-stage genomics-based non-invasive solution...
Cowen launched coverage of Alphatec Spine (NASDAQ:ATEC) with an “outperform” rating and $12 price target. The stock closed at $6.09 on Sept. 2. Alphatec designs, develops, manufactures and markets surgical spine...
Analysts for Raymond James and Cowen say two posters to be presented at the European Association of Urology (EAU) virtual conference in mid-July enhance the clinical utility of Profound Medical’s (NASDAQ:PROF;...
Cowen launched coverage of Stereotaxis (NYSE American:STXS) with an “outperform” rating and $6 price target. The stock closed at $2.71 on April 8. Genesis is Stereotaxis’ next-generation robotic magnetic navigation...
Cowen launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with an “outperform” rating and $15 (U.S.) price target. The stock closed at $9.74 on March 31. “[Profound’s] TULSA-PRO is a proprietary platform that...